Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 22

Cat.No. Product Name Information/Activity
BCN6291 Arctigenin Arctigenin is a lignan found in certain plants of the Asteraceae; it has shown antiviral and anticancer effects in glass; it is the aglycone of arctiin.
BCC5883 PDZ1 Domain inhibitor peptide 1315378-73-4
BCC4773 Cyclosporin A Cyclosporin A is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM. Cyclosporin A also inhibits CD11a/CD18 adhesion.
BCC5288 TRO 19622 Olesoxime (TRO 19622) is a mitochondrial-targeted neuroprotective compound with mean EC50 value for increasing cell survival is 3.2±0.2 µM.
BCC7952 Auranofin Auranofin (SKF-39162) is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.2 μM.
BCC6566 cis-ACPD 477331-06-9
BCC2894 H-D-Asp-OH (-)-Aspartic acid is an endogenous NMDA receptor agonist.
BCC2881 H-Asp-OH L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly.
BCC6571 L-Cysteinesulfinic acid L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92±0.03, 4.6±0.2, 3.9±0.2, 2.7±0.2, 4.0±0.2, and 3.94±0.08 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively.
BCC6013 GLYX 13 Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist.